Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer
Public ClinicalTrials.gov record NCT00479856. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Multi-centre Study of Lapatinib in Combinationwith Chemotherapy in Patients With ErbB2 Overexpressing Breastcancer After Trastuzumab Failure in the Neoadjuvant or Adjuvantsetting.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate the safety and efficacy of lapatinib in combination with chemotherapy (capecitabine, docetaxel, nab-paclitaxel) in subjects with ErbB2-overexpressing breast cancer whose disease has progressed during or within 12 months after completion of trastuzumab-containing therapy in the neoadjuvant or adjuvant setting.
Study identification
- NCT ID
- NCT00479856
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 9 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 2007 (Type not available)
- Primary completion
- Sep 2009 (Actual)
- Completion
- Mar 2010 (Actual)
- Last update posted
- Jun 5, 2012
2007 – 2010
United States locations
- U.S. sites
- 28
- U.S. states
- 18
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Hot Springs | Arkansas | 71913 | — |
| GSK Investigational Site | Anaheim | California | 92801 | — |
| GSK Investigational Site | Burbank | California | 91505 | — |
| GSK Investigational Site | Highland | California | 92346 | — |
| GSK Investigational Site | Long Beach | California | 90806 | — |
| GSK Investigational Site | Sacramento | California | 95819 | — |
| GSK Investigational Site | Washington D.C. | District of Columbia | 20007 | — |
| GSK Investigational Site | Fort Lauderdale | Florida | 33328 | — |
| GSK Investigational Site | Hollywood | Florida | 33021 | — |
| GSK Investigational Site | Orlando | Florida | 32806 | — |
| GSK Investigational Site | Atlanta | Georgia | 30341 | — |
| GSK Investigational Site | Lawrenceville | Georgia | 30045 | — |
| GSK Investigational Site | Zion | Illinois | 60099 | — |
| GSK Investigational Site | Indianapolis | Indiana | 46227 | — |
| GSK Investigational Site | Metairie | Louisiana | 70006 | — |
| GSK Investigational Site | New Orleans | Louisiana | 70112 | — |
| GSK Investigational Site | Baltimore | Maryland | 21237 | — |
| GSK Investigational Site | Minneapolis | Minnesota | 55426 | — |
| GSK Investigational Site | Tupelo | Mississippi | 38801 | — |
| GSK Investigational Site | Voorhees Township | New Jersey | 08043 | — |
| GSK Investigational Site | Albuquerque | New Mexico | 87131-0001 | — |
| GSK Investigational Site | New York | New York | 10016 | — |
| GSK Investigational Site | Sumter | South Carolina | 29150 | — |
| GSK Investigational Site | Austin | Texas | 78705 | — |
| GSK Investigational Site | San Antonio | Texas | 78229 | — |
| GSK Investigational Site | Ogden | Utah | 84403 | — |
| GSK Investigational Site | Abingdon | Virginia | 24211 | — |
| GSK Investigational Site | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00479856, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 5, 2012 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00479856 live on ClinicalTrials.gov.